Medesis Pharma SA (ALMDP) — Tangible Net Worth Ratio
Medesis Pharma SA (ALMDP) has a Tangible Net Worth Ratio of -99.3% as of June 2022. This metric is calculated by deducting intangible assets (€232.38K) from net assets (€116.62K) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. Also explore Medesis Pharma SA equity growth rate to track the company's year-over-year net asset growth rate.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Medesis Pharma SA Tangible Net Worth Ratio (2021–2021)
This chart shows how Medesis Pharma SA's Tangible Net Worth Ratio has changed across 1 annual periods from 2021 to 2021. As of June 2022, the ratio stands at -99.3%, reflecting net assets of €116.62K with intangible assets of €232.38K EUR. Check ALMDP PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Annual Tangible Net Worth Ratio for Medesis Pharma SA (2021–2021)
The table below presents the year-by-year Tangible Net Worth Ratio for Medesis Pharma SA from 2021 to 2021, covering 1 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For live market cap and overall valuation, see market value of Medesis Pharma SA.
| Year | Tangible NW Ratio | Net Assets (EUR) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2021 | 84.7% | €1.65 Million | €252.53K | €4.33 Million | — |